The controversy over a pricey rare-disease drug has ensnared the industry trade group for biotech companies, which is being challenged by a patent advocate to disavow “price gouging.”
In a letter to BIO chief executive Jim Greenwood, the Patients for Affordable Drugs wrote that the trade group has “an opportunity to disavow price gouging and exploitation of unrestrained market power” by Catalyst Pharmaceuticals, one of its members. The company has caused a furor over a drug with a $375,000 list price.
About the Author Reprints
Oh, goodness! Speak of the “devil” and he appears again! Apology for mixing media, but it’s where I just saw it: https://www.wsj.com/articles/martin-shkreli-steers-his-company-from-prisonwith-contraband-cellphone-11551973574?mod=hp_lead_pos1
If memory serves, didn’t BIO expel the once notorious “PharmaBro” (aka Martin S) and his RetroFin company for what is now by comparison a modest price for Daraprim? But times change … and my memory may be failing.
And whatever happened to the price of Daraprim? Just asking …
Oh, goodness! Speak of the “devil” and he appears again! Apology for mixing media, but it’s where I just saw it: https://www.wsj.com/articles/martin-shkreli-steers-his-company-from-prisonwith-contraband-cellphone-11551973574?mod=hp_lead_pos1